Information on OTFCS2

Basic details

Name: Otofaciocervical syndrome 2 | Acronym: OTFCS2
Alt. names: Fara-Chlupackova syndrome | OFC syndrome | PAX1 deficiency | Otofaciocervical syndrome

Gene: PAX1 | MOI: Autosomal recessive | Mechanism of action: Loss of Function

No. of cases in DB: 14 | First reported in: 2013

Last updated on: 2023-03-31 01:03:33 by Xiao P. Peng

OMIM: 615560

Orphanet: 2792

MONDO: 0014254

DOID: -

ClinGen: Definitive (2023-11-16)

Description

At least fourteen individuals from five unrelated families have now been described with this syndromic immunodeficiency resulting from biallelic PAX1 loss-of-function (LOF) mutations (PMID: 23851939, 28657137, 29681087, 32111619). Patients present with craniofacial dysmorphisms including microcephaly, a prominent forehead with frontal and parietal bossing, hypertelorism, nasolacrimal duct abnormalities, down-slanting palpebral fissures, epicanthal folds, long eyelashes, blue sclerae, small nose with depressed nasal bridge and hypoplastic nasal root, facial asymmetry due to facial nerve palsies, and retromicrognathia. Ears are particularly affected – patients show small, low-set malformed ears, with preauricular tags or pits, branchial fistulas and/or cysts, hypoplastic middle ear and internal auditory canals, and stenotic/atretic external auditory canals, often combining to result in mixed hearing loss. Additional musculoskeletal findings include low-set or malformed clavicles, protruding or sloping shoulders, winged scapulae, progressive weakness and hypotrophy of the scapular girdle, vertebral defects and kyphoscoliosis, as well as tapered fingers, bilateral clinodactyly and cutaneous syndactyly of the toes. Male patients may show bilateral cryptorchidism, while all patients may have short stature, developmental delays, and intellectual disability. From an immune perspective, thymic aplasia leads to a combined immunodeficiency picture, characterized by severe T cell lymphopenia (i.e. T− B+ NK+ SCID) and often resemblant of Omenn syndrome. Patients are affected by a broad spectrum of recurrent, early-onset infections of the bloodstream, skin, GI tract and sinorespiratory system including disseminated BCG infection after vaccination. In addition, they may show severe exfoliative dermatitis, chronic diarrhea, and lymphadenopathy. Labs are notable for markedly reduced proliferative responses to mitogens and antigens, variable hypogammaglobulinemia with often elevated serum IgE, and eosinophilia. Lymph node biopsy pathology may show severe lymphoid depletion with primary follicles without germinal centers.

Management

Antimicrobial prophylaxis is likely warranted for maximizing protection against infection. In the four patients for whom HSCT was tried, the profound T cell immunodeficiency of thymic origin failed to be corrected (PMID: 32111619). Only two patients were able to engraft with full donor chimerism but one failed to reconstitute T cells and developed severe autoimmune hemolytic anemia, requiring multiple courses of rituximab and immunosuppressive therapy. All T cells in the other patient showed a CD45R0+ phenotype, likely representing donor-derived T cells that had undergone peripheral expansion – this patient was awaiting thymic transplant at the time of report. Two others passed away from disease and/or transplant-related complications.

14 reported cases added to GenIA

SubjectID Sex Fam.ID AD AFM Validity Country Population Reference & Pub.code
102289arrow icon M 214934tree icon 20 0 Italy Moroccan PMID:28657137 [V:1(V.1)]; PMID:32111619 [Fam.B:V.4(P2)]
102294arrow icon F 214934tree icon 11 0 Italy Moroccan PMID:28657137 [Fam.V:1:V.18(V:18)]; PMID:32111619 [Fam.B:V.2(P3)]
102313arrow icon M 214935tree icon Turkey Turkish PMID:23851939 [V-2(V.2)]
102345arrow icon M 214935tree icon Turkey Turkish PMID:23851939 [Fam.V-2:IV.9(IV-9)]
102346arrow icon F 214935tree icon Turkey Turkish PMID:23851939 [Fam.V-2:IV.10(IV-10)]
102351arrow icon M 214935tree icon Turkey Turkish PMID:23851939 [Fam.V-2:V.3(V-3)]
102353arrow icon M 214936tree icon 3 0 India Indian PMID:29681087 [P1(II.1)]
102356arrow icon F 214936tree icon 0 0 India Indian PMID:29681087 [Fam.P1:II.2(P2)]
102357arrow icon M 214937tree icon 6 0 U.S.A. German PMID:32111619 [Fam.A:II.1(P1)]
102374arrow icon M 214944tree icon 0 Saudi Arabia Saudi PMID:32111619 [Fam.C:V.I(P7)]
102396arrow icon F 214944tree icon 1 0 Saudi Arabia Saudi PMID:32111619 [Fam.C:IV.4(P5)]
102397arrow icon F 214944tree icon 0 0 Saudi Arabia Saudi PMID:32111619 [Fam.C:IV.5(P6)]
102398arrow icon F 214944tree icon 4 0 Saudi Arabia Saudi PMID:32111619 [Fam.C:V.2(P4)]
105261arrow icon F 215680 13 0 Egypt Egyptian PMID:37924468 [Patient(III.1)]

AD: Age at genetic diagnosis; AFM: age at first manifestation; PMID: PubMed ID; GRID: GenIA reference ID (ref. not in PubMed).

Summary of clinical findings

[Considering only Definitive and Possible cases]

Rank Clinical term Present Absent Unreported
1 Microtiaarrow icon 8 (57.1%) 0 (0.0%) 6 (42.9%)
2 Low-set earsarrow icon 7 (50.0%) 0 (0.0%) 7 (50.0%)
3 Protruding shouldersarrow icon 7 (50.0%) 0 (0.0%) 7 (50.0%)
4 Short nosearrow icon 6 (42.9%) 0 (0.0%) 8 (57.1%)
5 Scapular wingingarrow icon 6 (42.9%) 1 (7.1%) 7 (50.0%)
6 Hearing impairmentarrow icon 6 (42.9%) 0 (0.0%) 8 (57.1%)
7 Hypertelorismarrow icon 5 (35.7%) 0 (0.0%) 9 (64.3%)
8 Abnormality of the pinnaarrow icon 5 (35.7%) 0 (0.0%) 9 (64.3%)
9 (unusual) Respiratory tract infectionarrow icon 5 (35.7%) 1 (7.1%) 8 (57.1%)
10 Enteropathyarrow icon 5 (35.7%) 0 (0.0%) 9 (64.3%)
11 Preauricular pitarrow icon 5 (35.7%) 3 (21.4%) 6 (42.9%)
12 Reduced T cell countarrow icon 5 (35.7%) 2 (14.3%) 7 (50.0%)
13 Depressed nasal bridgearrow icon 5 (35.7%) 0 (0.0%) 9 (64.3%)
14 Diarrheaarrow icon 5 (35.7%) 0 (0.0%) 9 (64.3%)
15 Hypogammaglobulinemiaarrow icon 5 (35.7%) 1 (7.1%) 8 (57.1%)
16 Cupped eararrow icon 4 (28.6%) 0 (0.0%) 10 (71.4%)
17 Downslanted palpebral fissuresarrow icon 4 (28.6%) 0 (0.0%) 10 (71.4%)
18 Hematopoietic stem cell transplantationarrow icon 4 (28.6%) 1 (7.1%) 9 (64.3%)
19 Lymphopeniaarrow icon 4 (28.6%) 1 (7.1%) 9 (64.3%)
20 Intellectual disabilityarrow icon 4 (28.6%) 0 (0.0%) 10 (71.4%)
21 Decreased IgM levelsarrow icon 4 (28.6%) 2 (14.3%) 8 (57.1%)
22 Abnormal lacrimal duct morphologyarrow icon 4 (28.6%) 0 (0.0%) 10 (71.4%)
23 Neurodevelopmental delayarrow icon 4 (28.6%) 0 (0.0%) 10 (71.4%)
24 Short neckarrow icon 3 (21.4%) 0 (0.0%) 11 (78.6%)
25 Eosinophiliaarrow icon 3 (21.4%) 3 (21.4%) 8 (57.1%)
26 Increased IgE levelsarrow icon 3 (21.4%) 2 (14.3%) 9 (64.3%)
27 Abnormal lymphoproliferationarrow icon 3 (21.4%) 3 (21.4%) 8 (57.1%)
28 Scoliosisarrow icon 3 (21.4%) 0 (0.0%) 11 (78.6%)
29 Thrombocytosisarrow icon 3 (21.4%) 0 (0.0%) 11 (78.6%)
30 Wide moutharrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
31 Decreased IgA levelsarrow icon 2 (14.3%) 4 (28.6%) 8 (57.1%)
32 Epicanthusarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
33 Microretrognathiaarrow icon 2 (14.3%) 1 (7.1%) 11 (78.6%)
34 Small foreheadarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
35 Stenosis of the external auditory canalarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
36 Long eyelashesarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
37 Nasolacrimal duct obstructionarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
38 Carious teetharrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
39 Lymphadenopathyarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
40 Hypoplastic scapulaearrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
41 Thin ribsarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
42 Short claviclesarrow icon 2 (14.3%) 1 (7.1%) 11 (78.6%)
43 Kyphosisarrow icon 2 (14.3%) 2 (14.3%) 10 (71.4%)
44 Lung diseasearrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
45 Abnormal vertebral morphologyarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
46 Facial palsyarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
47 Increased vertebral heightarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
48 Posterior scalloping of vertebral bodiesarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
49 Thymus aplasiaarrow icon 2 (14.3%) 2 (14.3%) 10 (71.4%)
50 Pneumoniaarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
51 Erythrodermaarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
52 Increased NK cell numberarrow icon 2 (14.3%) 1 (7.1%) 11 (78.6%)
53 Facial dysmorphismarrow icon 2 (14.3%) 2 (14.3%) 10 (71.4%)
54 Cryptorchidismarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
55 BCGitisarrow icon 2 (14.3%) 0 (0.0%) 12 (85.7%)
56 Triangular moutharrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
57 Parietal bossingarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
58 Retrognathiaarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
59 Facial asymmetryarrow icon 1 (7.1%) 3 (21.4%) 10 (71.4%)
60 Short chinarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
61 Mixed hearing impairmentarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
62 Atresia of the external auditory canalarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
63 Decreased IgG levelsarrow icon 1 (7.1%) 5 (35.7%) 8 (57.1%)
64 Underdeveloped nasal alaearrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
65 Eosinopeniaarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
66 Alacrimaarrow icon 1 (7.1%) 1 (7.1%) 12 (85.7%)
67 Blue scleraearrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
68 Thrombocytopeniaarrow icon 1 (7.1%) 4 (28.6%) 9 (64.3%)
69 Abnormal scapula morphologyarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
70 Cellulitisarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
71 Transverse facial cleftarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
72 Abnormal clavicle shapearrow icon 1 (7.1%) 1 (7.1%) 12 (85.7%)
73 Down-sloping shouldersarrow icon 1 (7.1%) 2 (14.3%) 11 (78.6%)
74 Platyspondylyarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
75 Syndactylyarrow icon 1 (7.1%) 1 (7.1%) 12 (85.7%)
76 Frontal bossingarrow icon 1 (7.1%) 1 (7.1%) 12 (85.7%)
77 Exaggerated cupid's bowarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
78 Reduced proportion of CD8 T cellsarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
79 Lymphocytosisarrow icon 1 (7.1%) 3 (21.4%) 10 (71.4%)
80 Increased number of B cellsarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
81 Neutropeniaarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
82 Conjunctivitisarrow icon 1 (7.1%) 2 (14.3%) 11 (78.6%)
83 Abnormality of the middle ear ossiclesarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
84 Postauricular pitarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
85 Beaking of vertebral bodiesarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
86 Spinal canal stenosisarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
87 Interstitial pneumonitisarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
88 Failure to thrivearrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
89 Lacrimal duct stenosisarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
90 Almond-shaped palpebral fissurearrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
91 Nail dystrophyarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
92 Hypoplastic vertebral bodiesarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
93 Morphological abnormality of the middle eararrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
94 Aplasia/Hypoplasia of the middle eararrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
95 Aplasia/Hypoplasia of the inner eararrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
96 Increased T cell countarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
97 Branchial anomalyarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
98 Malar prominencearrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
99 Skin rasharrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
100 Reduced proportion of CD4 T cellsarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
101 Prominent foreheadarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
102 Eczemaarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
103 Micrognathiaarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
104 Skin infections arrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
105 Delayed speech and language developmentarrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
106 Cleft palatearrow icon 1 (7.1%) 0 (0.0%) 13 (92.9%)
107 Periorbital dermoid cystarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
108 Microphthalmiaarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
109 Iris colobomaarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
110 Conical tootharrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
111 Salivary gland hypoplasiaarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
112 Gliosisarrow icon 0 (0.0%) 2 (14.3%) 12 (85.7%)
113 Immunodeficiencyarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
114 Hyperlordosisarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
115 Renal cystarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
116 Anterior scalloping of vertebral bodiesarrow icon 0 (0.0%) 2 (14.3%) 12 (85.7%)
117 Abnormality of thumb phalanxarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
118 Iris cystarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
119 Hypodontiaarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)
120 Renal agenesisarrow icon 0 (0.0%) 1 (7.1%) 13 (92.9%)

Summary of treatment outcomes

[Considering only Definitive and Possible cases]

Treatment ⓘ Responses & clinical indications
Hematopoietic stem cell transplantation Unspecified (4) for unspecified